{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:41:25Z","timestamp":1793328085578,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-025-00719-7","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:19:06Z","timestamp":1744780746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Cancer-associated venous thromboembolism: a comprehensive review"],"prefix":"10.1186","volume":"23","author":[{"given":"Tingting","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"719_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464\u201374.","journal-title":"Nat Rev Cardiol"},{"key":"719_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, B\u00fcller HR, S\u00f8rensen HT. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959\u201369.","journal-title":"Blood"},{"key":"719_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","volume":"103","author":"DP Cronin-Fenton","year":"2010","unstructured":"Cronin-Fenton DP, S\u00f8ndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, S\u00f8rensen HT. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997\u20132006. Br J Cancer. 2010;103:947\u201353.","journal-title":"Br J Cancer"},{"key":"719_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers12020367","volume":"12","author":"FI Mulder","year":"2020","unstructured":"Mulder FI, Bosch FTM, van Es N. Primary thromboprophylaxis in ambulatory cancer patients: where do we stand? Cancers (Basel). 2020;12:12.","journal-title":"Cancers (Basel)"},{"key":"719_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.V118.21.674.674","volume":"118","author":"AA Khorana","year":"2011","unstructured":"Khorana AA, Dalal M, Tangirala K, Miao R. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among U.S. Cancer patients. Blood. 2011;118:674\u2013674.","journal-title":"Blood"},{"key":"719_CR6","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood-2013-05-499087","volume":"122","author":"D Lillicrap","year":"2013","unstructured":"Lillicrap D. Introduction to a series of reviews on cancer-associated thrombotic disease. Blood. 2013;122:1687\u20138.","journal-title":"Blood"},{"key":"719_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2006-10-053736","volume":"110","author":"A Varki","year":"2007","unstructured":"Varki A. Trousseau\u2019s syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110:1723\u20139.","journal-title":"Blood"},{"key":"719_CR8","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712\u201323.","journal-title":"Blood"},{"key":"719_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632\u20134.","journal-title":"J Thromb Haemost"},{"key":"719_CR10","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT S\u00f8rensen","year":"2000","unstructured":"S\u00f8rensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846\u201350.","journal-title":"N Engl J Med"},{"key":"719_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2012.10.007","volume":"131","author":"G Gussoni","year":"2013","unstructured":"Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131:24\u201330.","journal-title":"Thromb Res"},{"key":"719_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/CMAR.S47094","volume":"5","author":"MH Amer","year":"2013","unstructured":"Amer MH. Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res. 2013;5:165\u201378.","journal-title":"Cancer Manag Res"},{"key":"719_CR13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00330-004-2252-1","volume":"14","author":"HJ Baarslag","year":"2004","unstructured":"Baarslag HJ, Koopman MM, Reekers JA, van Beek EJ. Diagnosis and management of deep vein thrombosis of the upper extremity: a review. Eur Radiol. 2004;14:1263\u201374.","journal-title":"Eur Radiol"},{"key":"719_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-0041-1722863","volume":"47","author":"SPS Dhami","year":"2021","unstructured":"Dhami SPS, Patmore S, O\u2019Sullivan JM. Advances in the management of cancer-associated thrombosis. Semin Thromb Hemost. 2021;47:139\u201349.","journal-title":"Semin Thromb Hemost"},{"key":"719_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8:11.","journal-title":"Nat Rev Dis Primers"},{"key":"719_CR16","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1172\/JCI930","volume":"101","author":"BM Mueller","year":"1998","unstructured":"Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest. 1998;101:1372\u20138.","journal-title":"J Clin Invest"},{"key":"719_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00043426-200005000-00019","volume":"22","author":"JS Palumbo","year":"2000","unstructured":"Palumbo JS, Degen JL. Hemostatic factors in tumor biology. J Pediatr Hematol Oncol. 2000;22:281\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"key":"719_CR18","first-page":"4549","volume":"51","author":"N Esumi","year":"1991","unstructured":"Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 1991;51:4549\u201356.","journal-title":"Cancer Res"},{"key":"719_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1055\/s-2007-991540","volume":"33","author":"E Sierko","year":"2007","unstructured":"Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007;33:712\u201321.","journal-title":"Semin Thromb Hemost"},{"key":"719_CR20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/ijms19041246","volume":"19","author":"S Wang","year":"2018","unstructured":"Wang S, Li Z, Xu R. Human cancer and platelet interaction, a potential therapeutic target. Int J Mol Sci. 2018;19:1246.","journal-title":"Int J Mol Sci"},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","volume":"10","author":"TA Waldmann","year":"2018","unstructured":"Waldmann TA. Cytokines in Cancer Immunotherapy. Cold Spring Harb Perspect Biol. 2018;10:a028472.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"719_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-0039-1693475","volume":"45","author":"D Mege","year":"2019","unstructured":"Mege D, Aubert M, Lacroix R, Dignat-George F, Panicot-Dubois L, Dubois C. Involvement of Platelets in Cancers. Semin Thromb Hemost. 2019;45:569\u201375.","journal-title":"Semin Thromb Hemost"},{"key":"719_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13058-019-1237-6","volume":"21","author":"HT Snoderly","year":"2019","unstructured":"Snoderly HT, Boone BA, Bennewitz MF. Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment. Breast Cancer Res. 2019;21:145.","journal-title":"Breast Cancer Res"},{"key":"719_CR24","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1172\/JCI67484","volume":"123","author":"J Cools-Lartigue","year":"2013","unstructured":"Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P, Ferri L. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446\u201358.","journal-title":"J Clin Invest"},{"key":"719_CR25","doi-asserted-by":"publisher","first-page":"eaao4227","DOI":"10.1126\/science.aao4227","volume":"361","author":"J Albrengues","year":"2018","unstructured":"Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, Upadhyay P, Uyeminami DL, Pommier A, K\u00fcttner V, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361:eaao4227.","journal-title":"Science"},{"key":"719_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/biom12020259","volume":"12","author":"ME Canonico","year":"2022","unstructured":"Canonico ME, Santoro C, Avvedimento M, Giugliano G, Mandoli GE, Prastaro M, Franzone A, Piccolo R, Ilardi F, Cameli M, Esposito G. Venous thromboembolism and cancer: a comprehensive review from pathophysiology to novel treatment. Biomolecules. 2022;12:259.","journal-title":"Biomolecules"},{"key":"719_CR27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.27772","volume":"119","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119:648\u201355.","journal-title":"Cancer"},{"key":"719_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cncr.20347","volume":"101","author":"SR Deitcher","year":"2004","unstructured":"Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101:439\u201349.","journal-title":"Cancer"},{"key":"719_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715\u201322.","journal-title":"JAMA"},{"key":"719_CR30","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902\u20137.","journal-title":"Blood"},{"key":"719_CR31","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","volume":"104","author":"FI Mulder","year":"2019","unstructured":"Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, Smit K, B\u00fcller HR, van Es N. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104:1277\u201387.","journal-title":"Haematologica"},{"key":"719_CR32","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1111\/jth.15503","volume":"19","author":"NAM Guman","year":"2021","unstructured":"Guman NAM, van Geffen RJ, Mulder FI, van Haaps TF, Hovsepjan V, Labots M, Cirkel GA, Y F L de Vos F, Ten Tije AJ, Beerepoot LV, et al. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer. J Thromb Haemost. 2021;19:2974\u201383.","journal-title":"J Thromb Haemost"},{"key":"719_CR33","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","volume":"116","author":"C Ay","year":"2010","unstructured":"Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377\u201382.","journal-title":"Blood"},{"key":"719_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","volume":"7","author":"M Verso","year":"2012","unstructured":"Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7:291\u20132.","journal-title":"Intern Emerg Med"},{"key":"719_CR35","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","volume":"22","author":"GT Gerotziafas","year":"2017","unstructured":"Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist. 2017;22:1222\u201331.","journal-title":"Oncologist"},{"key":"719_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","volume":"22","author":"CA Cella","year":"2017","unstructured":"Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist. 2017;22:601\u20138.","journal-title":"Oncologist"},{"key":"719_CR37","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","volume":"102","author":"N van Es","year":"2017","unstructured":"van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mah\u00e9 I, Wilts IT, Twint DC, Porreca E, Arrieta O, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102:1494\u2013501.","journal-title":"Haematologica"},{"key":"719_CR38","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.22.01542","volume":"41","author":"A Li","year":"2023","unstructured":"Li A, La J, May SB, Guffey D, da Costa WL Jr, Amos CI, Bandyo R, Milner EM, Kurian KM, Chen DCR, et al. Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems. J Clin Oncol. 2023;41:2926\u201338.","journal-title":"J Clin Oncol."},{"key":"719_CR39","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jth.14824","volume":"18","author":"N van Es","year":"2020","unstructured":"van Es N, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M, Briel M, Garcia D, Lyman GH, Macbeth F, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis. J Thromb Haemost. 2020;18:1940\u201351.","journal-title":"J Thromb Haemost"},{"key":"719_CR40","first-page":"1181","volume":"19","author":"MB Streiff","year":"2021","unstructured":"Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, Fertrin KY, Fogerty AE, Gao S, Goldhaber SZ, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Comprehens Cancer Net. 2021;19:1181\u2013201.","journal-title":"J Natl Comprehens Cancer Net"},{"key":"719_CR41","doi-asserted-by":"publisher","first-page":"454s","DOI":"10.1378\/chest.08-0658","volume":"133","author":"C Kearon","year":"2008","unstructured":"Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133:454s\u2013545s.","journal-title":"Chest"},{"key":"719_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146\u201353.","journal-title":"N Engl J Med"},{"key":"719_CR43","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330\u201393.","journal-title":"Eur Heart J"},{"key":"719_CR44","first-page":"Cd007557","volume":"4","author":"DR Junqueira","year":"2017","unstructured":"Junqueira DR, Zorzela LM, Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2017;4:Cd007557.","journal-title":"Cochrane Database Syst Rev"},{"key":"719_CR45","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/asheducation-2016.1.262","volume":"2016","author":"O Onwuemene","year":"2016","unstructured":"Onwuemene O, Arepally GM. Heparin-induced thrombocytopenia: research and clinical updates. Hematol Am Soc Hematol Educ Program. 2016;2016:262\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"719_CR46","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","volume":"344","author":"TE Warkentin","year":"2001","unstructured":"Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286\u201392.","journal-title":"N Engl J Med"},{"key":"719_CR47","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/MCC.0000000000000259","volume":"21","author":"TE Warkentin","year":"2015","unstructured":"Warkentin TE. Heparin-induced thrombocytopenia. Curr Opin Crit Care. 2015;21:576\u201385.","journal-title":"Curr Opin Crit Care"},{"key":"719_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","volume":"15","author":"C Frere","year":"2022","unstructured":"Frere C, Farge D, Schrag D, Prata PH, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2022;15:69.","journal-title":"J Hematol Oncol"},{"key":"719_CR49","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the chest guideline and expert panel report. Chest. 2021;160:2247\u201359.","journal-title":"Chest"},{"key":"719_CR50","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.3390\/curroncol28060453","volume":"28","author":"M Carrier","year":"2021","unstructured":"Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Suryanarayan D, Tagalakis V, Wu C, Lee AYY. Treatment algorithm in cancer-associated thrombosis: updated canadian expert consensus. Curr Oncol. 2021;28:5434\u201351.","journal-title":"Curr Oncol"},{"key":"719_CR51","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/bjh.18276","volume":"198","author":"KM Sanfilippo","year":"2022","unstructured":"Sanfilippo KM, Moik F, Candeloro M, Ay C, Di Nisio M, Lee AYY. Unanswered questions in cancer-associated thrombosis. Br J Haematol. 2022;198:812\u201325.","journal-title":"Br J Haematol"},{"key":"719_CR52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"719_CR53","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711\u20139.","journal-title":"N Engl J Med"},{"key":"719_CR54","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1055\/s-0041-1735251","volume":"122","author":"MA de Winter","year":"2022","unstructured":"de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, Klok FA, Moustafa F, Riva N, Ruiz Artacho PC, et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost. 2022;122:818\u201329.","journal-title":"Thromb Haemost"},{"key":"719_CR55","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36:2017\u201323.","journal-title":"J Clin Oncol"},{"key":"719_CR56","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1055\/s-0038-1667001","volume":"118","author":"N Kraaijpoel","year":"2018","unstructured":"Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost. 2018;118:1439\u201349.","journal-title":"Thromb Haemost"},{"key":"719_CR57","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1055\/s-0040-1720975","volume":"121","author":"W Ageno","year":"2021","unstructured":"Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, Becattini C, Agnelli G. Bleeding with Apixaban and Dalteparin in patients with cancer-associated venous thromboembolism: results from the caravaggio study. Thromb Haemost. 2021;121:616\u201324.","journal-title":"Thromb Haemost"},{"key":"719_CR58","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378:615\u201324.","journal-title":"N Engl J Med"},{"key":"719_CR59","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1111\/jth.14561","volume":"17","author":"M Di Nisio","year":"2019","unstructured":"Di Nisio M, van Es N, Carrier M, Wang TF, Garcia D, Segers A, Weitz J, Buller H, Raskob G. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019;17:1866\u201374.","journal-title":"J Thromb Haemost"},{"key":"719_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/530183","volume":"2011","author":"BH Chao","year":"2011","unstructured":"Chao BH, Lepeak L, Leal T, Robins HI. Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis. 2011;2011: 530183.","journal-title":"Thrombosis"},{"key":"719_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.115.2980.145","volume":"115","author":"L Kreisler","year":"1952","unstructured":"Kreisler L. Effect of heparin on the growth of a transplantable lymphosarcoma in mice. Science. 1952;115:145\u20136.","journal-title":"Science"},{"key":"719_CR62","first-page":"148","volume":"50","author":"V Bobek","year":"2003","unstructured":"Bobek V, Boubelik M, Kovar\u00edk J, Taltynov O. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine. Neoplasma. 2003;50:148\u201351.","journal-title":"Neoplasma"},{"key":"719_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biopha.2003.11.007","volume":"58","author":"V Bobek","year":"2004","unstructured":"Bobek V, Kovar\u00edk J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother. 2004;58:213\u20139.","journal-title":"Biomed Pharmacother"},{"key":"719_CR64","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1200\/JCO.2009.22.4584","volume":"27","author":"NM Kuderer","year":"2009","unstructured":"Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009;27:4902\u201311.","journal-title":"J Clin Oncol"},{"key":"719_CR65","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","volume":"11","author":"JL Stevenson","year":"2005","unstructured":"Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins\u2013correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005;11:7003\u201311.","journal-title":"Clin Cancer Res"},{"key":"719_CR66","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-03-1054","volume":"64","author":"RJ Ludwig","year":"2004","unstructured":"Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, Gille J. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004;64:2743\u201350.","journal-title":"Cancer Res"},{"key":"719_CR67","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.3390\/ijms22137053","volume":"22","author":"P Sarantis","year":"2021","unstructured":"Sarantis P, Bokas A, Papadimitropoulou A, Koustas E, Theocharis S, Papakotoulas P, Schizas D, Papalampros A, Felekouras E, Papavassiliou AG, Karamouzis MV. Combinatorial treatment of tinzaparin and chemotherapy can induce a significant antitumor effect in pancreatic cancer. Int J Mol Sci. 2021;22:7053.","journal-title":"Int J Mol Sci"},{"key":"719_CR68","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1517\/13543784.17.7.1029","volume":"17","author":"LR Zacharski","year":"2008","unstructured":"Zacharski LR, Lee AY. Heparin as an anticancer therapeutic. Expert Opin Investig Drugs. 2008;17:1029\u201337.","journal-title":"Expert Opin Investig Drugs"},{"key":"719_CR69","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/cncr.22892","volume":"110","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110:1149\u201361.","journal-title":"Cancer"},{"key":"719_CR70","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ctrv.2007.02.004","volume":"33","author":"V Tagalakis","year":"2007","unstructured":"Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev. 2007;33:358\u201368.","journal-title":"Cancer Treat Rev"},{"key":"719_CR71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.critrevonc.2006.07.007","volume":"61","author":"TM Niers","year":"2007","unstructured":"Niers TM, Klerk CP, DiNisio M, Van Noorden CJ, B\u00fcller HR, Reitsma PH, Richel DJ. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol. 2007;61:195\u2013207.","journal-title":"Crit Rev Oncol Hematol"},{"key":"719_CR72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(24)01481-9","volume":"53","author":"SM Smorenburg","year":"2001","unstructured":"Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53:93\u2013105.","journal-title":"Pharmacol Rev"},{"issue":"Suppl 2","key":"719_CR73","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/S0049-3848(10)70017-7","volume":"125","author":"L Borsig","year":"2010","unstructured":"Borsig L. Antimetastatic activities of heparins and modified heparins. Exper Evid Thromb Res. 2010;125(Suppl 2):S66-71.","journal-title":"Exper Evid Thromb Res"},{"key":"719_CR74","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Mu\u00f1oz A, Brenner B, Prata PH, Brilhante D, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23:e334\u201347.","journal-title":"Lancet Oncol"},{"key":"719_CR75","doi-asserted-by":"publisher","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","volume":"22","author":"MB Streiff","year":"2024","unstructured":"Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin KY, Fogerty AE, Crestani NG, Gangaraju R, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:483\u2013506.","journal-title":"J Natl Compr Canc Netw"},{"key":"719_CR76","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","volume":"5","author":"BJ Carney","year":"2021","unstructured":"Carney BJ, Wang TF, Ren S, George G, Al Homssi A, Gaddh M, Connolly GC, Shah VI, Bogue T, Bartosic A, et al. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv. 2021;5:5546\u201353.","journal-title":"Blood Adv"},{"key":"719_CR77","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927\u201374.","journal-title":"Blood Adv"},{"key":"719_CR78","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jth.15599","volume":"20","author":"F Moik","year":"2022","unstructured":"Moik F, Colling M, Mah\u00e9 I, Jara-Palomares L, Pabinger I, Ay C. Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost. 2022;20:619\u201334.","journal-title":"J Thromb Haemost"},{"key":"719_CR79","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","volume":"157","author":"L Jara-Palomares","year":"2017","unstructured":"Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M, Blasco-Esquivias I, Marin-Barrera L, de la Borbolla-Artacho MR, Praena-Fernandez JM, Montero-Romero E, Navarro-Herrero S, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017;157:90\u20136.","journal-title":"Thromb Res"},{"key":"719_CR80","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1182\/bloodadvances.2020003115","volume":"4","author":"FTM Bosch","year":"2020","unstructured":"Bosch FTM, Mulder FI, Kamphuisen PW, Middeldorp S, Bossuyt PM, B\u00fcller HR, van Es N. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv. 2020;4:5215\u201325.","journal-title":"Blood Adv"},{"key":"719_CR81","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566\u201381.","journal-title":"Lancet Oncol"},{"key":"719_CR82","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3324\/haematol.2019.222828","volume":"105","author":"A Delluc","year":"2020","unstructured":"Delluc A, Miranda S, Exter PD, Louzada M, Alatri A, Ahn S, Monreal M, Khorana A, Huisman MV, Wells PS, Carrier M. Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica. 2020;105:1436\u201342.","journal-title":"Haematologica"},{"key":"719_CR83","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/a-1486-7497","volume":"122","author":"P Girard","year":"2022","unstructured":"Girard P, Laporte S, Chapelle C, Falvo N, Falchero L, Cloarec N, Monnet I, Burnod A, Tomasini P, Boulon C, et al. Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study. Thromb Haemost. 2022;122:151\u20137.","journal-title":"Thromb Haemost"},{"key":"719_CR84","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/jth.15153","volume":"19","author":"JK Schaefer","year":"2021","unstructured":"Schaefer JK, Li M, Wu Z, Basu T, Dorsch MP, Barnes GD, Carrier M, Griggs JJ, Sood SL. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. J Thromb Haemost. 2021;19:212\u201320.","journal-title":"J Thromb Haemost"},{"key":"719_CR85","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","volume":"100","author":"S Noble","year":"2015","unstructured":"Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 2015;100:1486\u201392.","journal-title":"Haematologica"},{"key":"719_CR86","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/jth.13659","volume":"15","author":"I Elalamy","year":"2017","unstructured":"Elalamy I, Mah\u00e9 I, Ageno W, Meyer G. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. J Thromb Haemost. 2017;15:848\u201357.","journal-title":"J Thromb Haemost"},{"key":"719_CR87","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.thromres.2020.06.024","volume":"194","author":"I Mah\u00e9","year":"2020","unstructured":"Mah\u00e9 I, Chidiac J, Pinson M, Pinson M, Swarnkar P, Nelson A, Noble S. Patients experience of living with cancer associated thrombosis in France (Le PELICAN). Thromb Res. 2020;194:66\u201371.","journal-title":"Thromb Res"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00719-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:02:15Z","timestamp":1744790535000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00719-7","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}